Multicentre, phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer: TG1308 study

BACKGROUND & AIMS: Gemcitabine plus cisplatin (GC) remains the standard, frontline therapy for advanced biliary tract cancer (ABTC). The JCOG1113 study suggested that gemcitabine plus S‐1 (GS) had noninferior median overall survival and comparable incidence of significant neutropenia as compared...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Liver Int
Main Authors: Chiang, Nai‐Jung, Chen, Ming‐Huang, Yang, Shih‐Hung, Hsu, Chiun, Yen, Chia‐Jui, Tsou, Hsiao‐Hui, Su, Yung‐Yeh, Chen, Jen‐Shi, Shan, Yan‐Shen, Chen, Li‐Tzong
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Liver Cancer
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540301/
https://ncbi.nlm.nih.gov/pubmed/32463975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/liv.14538
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki